Ownership
Private
Employees
~813
Therapeutic Areas
ImmunologyPulmonologyGastroenterologyInfectious Diseases
Stage
Commercial
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Small molecules (oral solids, oral liquids, semisolids)Hormonal injectablesInhaled biological products

Carnot Laboratorios General Information

Carnot Laboratorios has over eight decades of experience developing and commercializing pharmaceutical products for Latin America. The company focuses on innovative medicines for common ailments across several therapeutic areas including gastroenterology and respiratory disease. It operates two production facilities in Mexico and exports to more than fifteen countries. Recent investments include a new state-of-the-art manufacturing plant in Hidalgo to expand capacity and global reach.[5] No recent clinical trial results are publicly highlighted.

Contact Information

Primary Industry
Biotech
Corporate Office
Mexico City, CDMX
Mexico

Drug Pipeline

tegoprazan
Commercial
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Carnot Laboratorios's pipeline data

Book a demo

Key Partnerships

Acerus Pharmaceuticals – licensing agreement for NATESTO® testosterone therapy covering Central & Latin America.

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Carnot Laboratorios Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Carnot Laboratorios's complete valuation and funding history, request access »

Carnot Laboratorios Financial Metrics